- Home
- SILC vs CLYM Comparison
SILC vs CLYM Comparison
Compare SILC & CLYM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SILC
- CLYM
- Stock Information
- Founded
- SILC 1987
- CLYM 2018
- Country
- SILC Israel
- CLYM United States
- Employees
- SILC N/A
- CLYM N/A
- Industry
- SILC Computer Manufacturing
- CLYM
- Sector
- SILC Technology
- CLYM
- Exchange
- SILC Nasdaq
- CLYM NYSE
- Market Cap
- SILC 85.1M
- CLYM 83.8M
- IPO Year
- SILC 1994
- CLYM 2021
- Fundamental
- Price
- SILC $15.20
- CLYM $1.26
- Analyst Decision
- SILC Hold
- CLYM Buy
- Analyst Count
- SILC 2
- CLYM 1
- Target Price
- SILC N/A
- CLYM $10.00
- AVG Volume (30 Days)
- SILC 11.0K
- CLYM 416.7K
- Earning Date
- SILC 07-31-2025
- CLYM 08-13-2025
- Dividend Yield
- SILC N/A
- CLYM N/A
- EPS Growth
- SILC N/A
- CLYM N/A
- EPS
- SILC N/A
- CLYM N/A
- Revenue
- SILC $58,134,000.00
- CLYM N/A
- Revenue This Year
- SILC $6.26
- CLYM N/A
- Revenue Next Year
- SILC $19.14
- CLYM N/A
- P/E Ratio
- SILC N/A
- CLYM N/A
- Revenue Growth
- SILC N/A
- CLYM N/A
- 52 Week Low
- SILC $11.35
- CLYM $1.05
- 52 Week High
- SILC $18.24
- CLYM $9.21
- Technical
- Relative Strength Index (RSI)
- SILC 50.71
- CLYM N/A
- Support Level
- SILC $14.99
- CLYM N/A
- Resistance Level
- SILC $16.00
- CLYM N/A
- Average True Range (ATR)
- SILC 0.55
- CLYM 0.00
- MACD
- SILC -0.01
- CLYM 0.00
- Stochastic Oscillator
- SILC 44.83
- CLYM 0.00
About SILC Silicom Ltd
Silicom Ltd designs and manufactures networking and data infrastructure solutions for various servers, server-based systems, and communications devices. Its product categories consist of Server Adapters, Edge Networking Solutions, FPGA-Based Cards, x86 Open Appliances, Bypass Switches, and TAPs. Geographically, it derives a majority of its revenue from North America and also has a presence in Europe and Asia-Pacific.
About CLYM CLIMB BIO INC
Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. its product candidate, budoprutug, is an anti-CD19 monoclonal antibody that has demonstrated B-cell depletion and has the potential to treat a broad range of B-cell-mediated diseases.